Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ZYME · against 394 other Healthcare companies of similar size
Ranked #287 of 395 · scores higher than 6% of peers
Bars: peers in each 10-point band of the valuation score109 peers with a valuation score of 0–9, including ZYME · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | ZYME | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 384 reported | -6.7% | 1.7% | 20% | 30% | |
| EBITDA yieldHigher is better · 395 reported | -8.0% | 4.3% | 15% | 50% | |
| Free cash flow yieldHigher is better · 194 reported | -5.6% | -0.6% | 30% | 20% | |
| Book yieldHigher is better · 386 reported | 3.7% | 34.1% | 8% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 287 | 3.7B USD | 8 | 28 | |
| 287 | 2.3B USD | 8 | 27 | |
| 287 | 1.8B USD | 8 | 23 | |
| 287 | 2.5B USD | 8 | 31 | |
| 287 | 2.2B USD | 8 | 20 | |
| 372 | 162.9B JPY (≈$1.1B) | 7 | 46 | |
| 372 | 18.5B CNY (≈$2.6B) | 7 | 37 | |
| 374 | 9.3B CNY (≈$1.3B) | 0 | 32 | |
| 374 | 9.6B CNY (≈$1.3B) | 0 | 27 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score